Injection Site Reactions In placebo-controlled trials, injection site reactions (e.g., injection-site discomfort, erythema) were reported in 0.2% of OZEMPIC-treated patients
Many compounded semaglutide prescribers never titrate patients to the higher doses where the medication produces its strongest effects
All reported findings originate from structured laboratory or regulated human clinical research environments
He expresses confidence in combining the two peptides, despite the lack of clinical research demonstrating the safety of using them together
Avoid fried or fatty foods and dishes heavy on cheese, which can increase bloating, diarrhea and other GI symptoms
Holding at a dose for an extra 4 weeks before escalating is a medically supported strategy when: Nausea or vomiting persists beyond 2 weeks at the current dose You are unable to eat at least 1,000 calories per day comfortably Dehydration symptoms appear (dark urine, dizziness on standing, dry mouth) You are losing weight faster than 1 to 2 pounds per week on the current dose (aggressive weight loss increases side effect risk) In the STEP trials, delayed escalation did not compromise overall weight loss outcomes at 68 weeks
